Compare Enveric Biosciences Inc (ENVB) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Simon Property Group Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Simon Property Group Inc trades at $199.6 (market cap $63.93B). The key difference: Simon Property Group Inc is far larger — about 9556.1× Enveric Biosciences Inc's market cap, and Simon Property Group Inc pays a 4.5% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Simon Property Group Inc for 99 Days on average.
| ENVB | SPG | |
|---|---|---|
Market Cap | $6.69M | $63.93B |
Volume | 41,141 | 1,228,229 |
Sector | Health | Real Estate |
52-Week High | $10.80 | $236.70 |
52-Week Low | $1.27 | $173.35 |
Typical Hold Time | 14 Days | 99 Days |
Enterprise Value | -$1.60M | $92.38B |
Dividend Yield | — | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
SPG trades at $199.61, down 1.06% on the day, amid a bearish technical setup with resistance near $200 and support at $195. Fundamentally, the REIT shows strong profitability with a net income margin of 66.57% and a P/E of 13.94, while recent news highlights leasing strength and a new media network launch. Cash flow trends show operational stability but negative net cash flow in 2025.
The outlook is mixed: analyst consensus is a Buy with a $222.90 price target, but technical indicators signal caution. Opportunities include high profitability and dividend yield; risks involve debt maturities and interest rate sensitivity. The stock offers value if operational momentum continues, but investors should weigh near-term technical pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
